Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow device compared to a nucleocapsid-only device
C. A. Linares, F. Ryan, S. E. Moses
The paper withdraws a manuscript due to the need for further experiments to validate conclusions about a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow device compared to a nucleocapsid-only device.
bioRxiv · Jul 1, 2020Immunology